Wolverine Trading, LLC Arvinas, Inc. Call Options Transaction History

Wolverine Trading, LLC

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$23.66 - $32.73 $411,684 - $569,502	17,400 Added 87.88%	37,200 $916,000
Q2 2024 Aug 14, 2024	BUY	$24.46 - $40.4 $198,126 - $327,240	8,100 Added 69.23%	19,800 $527,000
Q1 2024 May 15, 2024	SELL	$36.38 - $52.31 $14,552 - $20,924	-400 Reduced 3.31%	11,700 $482,000
Q4 2023 Feb 14, 2024	BUY	$14.19 - $42.33 $171,699 - $512,193	12,100 New	12,100 $498,000
Q1 2023 May 15, 2023	SELL	$26.15 - $37.26 $99,370 - $141,588	-3,800 Reduced 30.89%	8,500 $228,000
Q4 2022 Feb 14, 2023	BUY	$32.47 - $57.24 $399,381 - $704,052	12,300 New	12,300 $421,000
Q2 2022 Aug 15, 2022	SELL	$36.01 - $74.24 $270,075 - $556,800	-7,500 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$60.27 - $81.57 $452,025 - $611,775	7,500 New	7,500 $479,000
Q2 2021 Aug 06, 2021	SELL	$60.45 - $84.26 $308,295 - $429,726	-5,100 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$58.19 - $91.37 $296,769 - $465,987	5,100 New	5,100 $319,000

229

68.4M

226K

285K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $983M
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Wolverine Trading, LLC with notifications on news.